<ul>
<li>Incyte expanded its molecular AI drug-discovery collaboration with Genesis Molecular AI, broadening use of the GEMS platform across more targets in its pipeline.     *      Genesis will receive USD 120 million upfront, including USD 80 million in cash, USD 40 million in equity, with additional recurring research funding for model training and compute.     *      The partners plan to add at least five new discovery targets selected by Incyte, with options to nominate more over time.     *      Genesis is eligible for milestone payments of up to USD 232 million per program, with aggregate potential of more than USD 1 billion across the initial five targets, subject to performance thresholds.     *      Incyte will hold exclusive rights to develop and commercialize any products from the collaboration, with Genesis also eligible for royalties on sales of approved products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200800BIZWIRE_USPR_____20260520_BW680248) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

INCY

LABU

ARKG

<p>Incyte has expanded its collaboration with Genesis Molecular AI, paying USD 120 million upfront, which includes USD 80 million in cash and USD 40 million in equity. The partnership aims to broaden the use of the GEMS platform across more targets, with potential milestone payments exceeding USD 1 billion. Incyte retains exclusive rights to develop and commercialize products from this collaboration.</p>

Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront